Dr. Brose Describes the DECISION Trial

Marcia S. Brose, MD, PhD
Published: Tuesday, Dec 03, 2013

Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Brose explains that the DECISION trial was a placebo-controlled, randomized trial that tested the efficacy of sorafenib in patients with differentiated thyroid cancer that had progressed following radioactive iodine. These patients were randomized 1:1 to either sorafenib or placebo.

Brose says the results showed that the progression-free survival in the sorafenib arm was significantly increased to 10.8 months compared to 5.8 months in the placebo arm. This data is statistically significant with a hazard ratio of .587 and a P value of less than .0001.

SELECTED
LANGUAGE
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, describes the DECISION trial, which analyzed the efficacy of sorafenib in differentiated thyroid cancer.

Brose explains that the DECISION trial was a placebo-controlled, randomized trial that tested the efficacy of sorafenib in patients with differentiated thyroid cancer that had progressed following radioactive iodine. These patients were randomized 1:1 to either sorafenib or placebo.

Brose says the results showed that the progression-free survival in the sorafenib arm was significantly increased to 10.8 months compared to 5.8 months in the placebo arm. This data is statistically significant with a hazard ratio of .587 and a P value of less than .0001.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x